HEOR provides evidence that demonstrates the value, cost-effectiveness, and real-world impact of a product. This evidence supports regulatory approvals, reimbursement decisions, and market access strategies.
- Pharmaceutical and biotechnology companies
- Medical device manufacturers
- Payers and insurance providers
- Policymakers and regulators
- Academic researchers and healthcare providers
- Cost-effectiveness analysis (CEA)
- Budget impact analysis (BIA)
- Cost-utility analysis (CUA)
- Real-world evidence (RWE) studies
- Patient-reported outcomes (PROs)
- Systematic literature reviews and meta-analyses
- Health technology assessment (HTA) submissions
By providing robust economic models and real-world data, HEOR demonstrates how a treatment improves patient outcomes while being cost-effective. This evidence helps companies negotiate pricing, reimbursement, and formulary placement with payers and regulators.
HEOR helps providers understand which treatments deliver the best outcomes for patients at sustainable costs, guiding evidence-based care delivery and resource allocation.
Yes. Many HEOR studies are published in reputed journals such as Value in Health, Pharmacoeconomics, and Health Economics. We also support clients in manuscript writing and submission.
- Multidisciplinary team of health economists, statisticians, and clinical experts
- Global compliance with ISPOR, HTA, and regulatory guidelines
- Advanced modeling and AI/ML-driven analytics
- End-to-end support from study design to publication












